
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics is well-positioned for future success, with its strong scientific understanding of integrin biology and a highly experienced management team that has successfully navigated the regulatory landscape. Despite early stage clinical pipeline, the company's meticulously designed trials and promising data from its lead program provide evidence of a potentially successful commercial product in the making. Additionally, PLNRX's management team, with a proven track record of drug launches, further mitigates the potential commercial risk for the company.
Bears say
Pliant Therapeutics is positioned to unlock significant value through its novel integrin-targeting delivery platform that has the potential to target specific tissue types based on cell-specific integrin receptors. With a focus on siRNA delivery, the company's programs have the potential for broad applications across multiple disease areas. This innovative platform is a key value driver for Pliant Therapeutics and could lead to future success.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares